TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03641118

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
Study: NCT01289509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Lot P01010ZZA (test) single oral doses of 40 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: E5501
Description: Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
Study: NCT03772639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making
Description: Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
Study: NCT03141177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study: NCT06775652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Patients assigned to the NCRT group received intravenous paclitaxel (135 mg/m²) and carboplatin (AUC=2-5) on day 1, administered every three weeks for two cycles. Concurrently, they received intensity-modulated radiotherapy (IMRT) with a total of 20 sessions (CTV 40 Gy, GTV 44 Gy) five days per week. All radiotherapy plans were reviewed by designated radiation oncologists before treatment to ensure quality control. Patients were assessed 4 to 6 weeks after completing NCRT following RECIST 1.1 criteria.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant therapy
Description: Patients in the AT group received surgery as soon as possible after randomization, followed by adjuvant therapy, postoperative adjuvant therapy based on pathological staging, as recommended by the NCCN Clinical Practice Guidelines for Esophageal and Esophagogastric Junction Cancers (2017 V4), starting one month post-surgery with either adjuvant chemotherapy or chemoradiotherapy. The adjuvant chemotherapy regimen was the same as the neoadjuvant chemotherapy regimen, and the adjuvant radiotherapy regimen and dose were administered according to guideline recommendations.
Study: NCT03141177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Specified dose on specified days
Study: NCT06775652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT03141177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Specified dose on specified days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT04728113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive care visit with questionnaires
Description: 5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oncological standard visit
Description: Oncological standard visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncological standard visit
Description: Oncological standard visit
Study: NCT03279484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIGO 4LV lead implant
Description: All patients will be attempted to implant or implanted with NAVIGO 4LV lead
Study: NCT00947011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet 100 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Januvia
Description: 1 tablet 100 mg once a day
Study: NCT04527887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)
Description: Intracanalicular dexamethasone insert contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for up to 30 days for the reduction of postsurgical inflammation and pain associated with ocular surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProLong™ collagen plugs
Description: The long term synthetic punctal plug is composed of an absorbable copolymer material and measures 0.4mm in diameter and 2.0mm in length.
Study: NCT02201927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galvanic vestibular stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galvanic vestibular stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: galvanic vestibular stimulation
Study: NCT04525391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab+AZD2811 to SCLC patients
Description: AZD2811 must NOT be infused through a 0.2-µm or 0.22-µm filter and therefore durvalumab and AZD2811 MUST be infused through different infusion lines. In order not to exceed the endotoxin limit, durvalumab and AZD2811 mustbe administered consecutively. Durvalumab is administered first over 1 hour, followed by AZD2811 administered over 2 hours. AZD2811 should be administered at 30 minutes after the end of the durvalumab infusion, as long as there are no acute infusion reactions to durvalumab.
Study: NCT03297788

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS
Description: For SRS the dose prescription to the PTV will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
Study: NCT01907087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 190
Description: 30-300 mg ICV infusion administered every other week for at least 48 weeks.
Study: NCT02984839

Intervention type: DEVICE
Intervention: Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology
Description: Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450

Intervention type: DEVICE
Intervention: Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology
Description: Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
Study: NCT02850523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Perinatal Anxiety
Description: The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
Study: NCT03642574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CNV
Description: Embryo with euploid chromosome will transfer to uterus. The order of transfer is accroding to morphological grade.
Study: NCT04793503

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional complete denture
Description: the complete denture constructed by packing technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CADCAM 3D printed denture
Description: The files from the laser-scan will be translated into stereolithography (STL) files and the CDs are virtually designed in ExoCad software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM milled denture
Description: Once the complete denture has been virtually designed in CAD software (ExoCad software) a preview will be sent for evaluation using 3D viewing software
Study: NCT03000400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Traumatic Brain Injury Family System Intervention.
Description: Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational session at OUH
Description: 2.5 hour psycho-educational session for the patient's family members.
Study: NCT03246698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolytic Stretching group
Description: In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching group
Description: In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
Study: NCT02203461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
Description: STRIBILD® QD, d1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
Description: Truvada®/ Kaletra® 200/50 mg QD, d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
Description: Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
Study: NCT03796988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Regeneration of Tissue (ART) device
Description: This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
Study: NCT01292603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-3 or Days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-3 or Days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-3 or Days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 1-3 or Days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 1-3 or Days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days 1-3 or Days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: 6 cycles of intravenous MabThera
Study: NCT04207099

Intervention type: DEVICE
Intervention: MolecuLight i:X Imaging Device
Description: The MolecuLight i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
Study: NCT03641482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBF
Description: Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
Study: NCT00846664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Short Arc Banding
Description: Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
Study: NCT04390438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrolysis
Description: Needle emplacement with a galvanic electrical current

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrolysis
Description: Needle emplacement with a galvanic electrical current

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Needle emplacement without electrical current nor substance
Study: NCT03426306

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 4DCT-Ventilation
Description: 4DCT-ventilation is an imaging modality that provides superior image quality, reduced cost, and a faster imaging procedure compared to nuclear medicine VQ scans.
Study: NCT03137511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
Description: Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
Study: NCT05615792

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00857324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~* Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~* In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Study: NCT03031691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brontictuzumab
Description: starting dose of 1.5mg/kg administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trifluridine/tipiracil
Study: NCT03962387

Intervention type: OTHER
Intervention: Not applicable(observational study)
Description: Not applicable(observational study)
Study: NCT02041195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Setmelanotide
Study: NCT02032134

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Transfusion of Pooled Platelets Cryopreserved In DMSO
Description: Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing
Study: NCT03464188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Cornerstone
Description: Project Cornerstone basic elements are:~1. The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician;~2. 6 base telephone/in-person sessions: Sessions cover specific topics (every 1-2 weeks, 20-60 minutes/session; by phone or in-person), followed by monthly follow-up and additional coaching sessions as needed;~3. Regular caregiver distress thermometer screening and problem support and self-care coaching.~4. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions. Project Cornerstone begins within 60 days of a care recipient being diagnosed with advanced cancer and ends 1 year after care recipient death.
Study: NCT02041195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Setmelanotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04457232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 FAPi-46
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT imaging
Study: NCT00808912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg ingested orally 1 hour prior to exercise testing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 50 mg ingested orally 1 hour prior to exercise testing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
Study: NCT04086953

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walk-Time Limit Tes
Description: Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walk-Time Limit Tes
Description: Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
Study: NCT02041195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo